CDKN2A sirna

CDKN2A siRNA (Mouse)

Cat. Num. AAA8218209

• Gene Names: Cdkn2a; Arf; p16; MTS1; Pctr1; p19ARF; p16INK4a; p19<ARF>; ARF-INK4a; INK4a-ARF; Ink4a/Arf; p16(INK4a)
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CDKN2A; CDKN2A siRNA (Mouse); P16INK4A; Cyclin-dependent kinase inhibitor 2A isoforms 1/2; Cyclin-dependent kinase 4 inhibitor A; CDK4I; p16-INK4a; p16-INK4; CDKN2A sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: CDKN2A siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 168

• Applicable Applications for CDKN2A sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse CDKN2A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CDKN2A sirna

siRNA to inhibit CDKN2A expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 98986447
• NCBI GeneID: 12578
• NCBI Accession #: NP_001035744.1
• NCBI GenBank Nucleotide #: NM_001040654.1
• UniProt Accession #: P51480; O89088; P97510; P97937; Q6PEA2; Q78E39; Q78E57; Q792X7; Q9QWH6; Q9QWH7; A2ANM1; A2ANM2; Q64364
• Molecular Weight: 19,238 Da
• NCBI Official Full Name: cyclin-dependent kinase inhibitor 2A isoform 2
• NCBI Official Synonym Full Names: cyclin-dependent kinase inhibitor 2A
• NCBI Official Symbol: Cdkn2a
• NCBI Official Synonym Symbols: Arf; p16; MTS1; Pctr1; p19ARF; p16INK4a; p19<ARF>; ARF-INK4a; INK4a-ARF; Ink4a/Arf; p16(INK4a)
• NCBI Protein Information: cyclin-dependent kinase inhibitor 2A
• UniProt Protein Name: Cyclin-dependent kinase inhibitor 2A
• Protein Family: CDKN2A-interacting protein
• UniProt Gene Name: Cdkn2a
• UniProt Synonym Gene Names: CDK4I; p16-INK4
• UniProt Entry Name: CDN2A_MOUSE

Uniprot Description

p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.

Protein type: Cell cycle regulation; Tumor suppressor; Nucleolus

Cellular Component: nucleoplasm; nuclear body; granular component; protein complex; mitochondrion; cytoplasm; nucleolus; nucleus

Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; transcription factor binding; protein kinase binding; transcription factor activity

Biological Process: epidermis development; protein polyubiquitination; somatic stem cell maintenance; positive regulation of apoptosis; apoptosis; positive regulation of transcription, DNA-dependent; positive regulation of apoptosis involved in mammary gland involution; regulation of protein stability; negative regulation of B cell proliferation; glucose homeostasis; response to organic cyclic substance; negative regulation of cell cycle; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of transcription, DNA-dependent; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; negative regulation of protein binding; aging; caspase activation; negative regulation of immature T cell proliferation in the thymus; response to drug; protein stabilization; transcription, DNA-dependent; protein destabilization; negative regulation of cyclin-dependent protein kinase activity; cell aging; response to organic nitrogen; cell cycle; negative regulation of cell-matrix adhesion; negative regulation of mammary gland epithelial cell proliferation; rRNA transcription; positive regulation of protein sumoylation; regulation of gene expression; inhibition of NF-kappaB transcription factor; regulation of nucleocytoplasmic transport; negative regulation of ubiquitin-protein ligase activity; negative regulation of protein kinase activity; negative regulation of phosphorylation; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; negative regulation of cell growth; positive regulation of DNA damage response, signal transduction by p53 class mediator; regulation of cyclin-dependent protein kinase activity; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle